Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
Subscribe To Our Newsletter & Stay Updated
